Immunic is trading 5.19% down at $14.98 after broader risk-off pressure hit biotechnology and growth stocks on September 1, 2026.
- Biotech ETF XBI is down 4.24%, while the S&P 500 and Nasdaq are also lower.
- Geopolitical tensions, higher oil prices, rising yields, and softer economic data are weighing on risk appetite.
- Immunic announced a data-and-digital officer appointment; no company-specific negative catalyst was identified.